Hodgkin’s Lymphoma

Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

RATHL
Type: Multi-centre, randomised phase III study
Eligibility: A randomised trial to assess response adapted therapy using FDG-PET in patients with newly diagnosed, advanced Hodgkin’s Lymphoma
Study details: Histologically confirmed classical Hodgkin lymphoma (HL) according to the current World Health Organisation Classification (nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted). Age 18 or above. Clinical stage IIB,IIIA, IIIB or IV, or Clinical stage IIA with adverse features. No previous chemotherapy, radiotherapy or other investigational drug for HL. Performance status 0-3.
National Study of Hodgkin’s Lymphoma Genetics
Type: Genetics study
Eligibility: The purpose of this study is to collect information from individuals with a diagnosis of Hodgkin’s Lymphoma, in order to identiy hereditary factors (genes) that may affect the risk of the condition.
Study details: To establish a large DNA resource in Britain to enable (i) Identification of genetic suspectibility variants for Hodgkin Lymphoma (HL) through association-based analysis. (ii) in the longer term, investigation of inherited genetic factors affecting risk of second cancers and other late adverse events after HL.
ReACH
Type: Multicentre, phase II study
Eligibility: A confirmed diagnosis of Hodgkin Lymphoma. HLA matched sibling donor. Relapse following first remission, and in complete or partial remission (using standard criteria) following salvage therapy, but with residual FDG-avid lesions. Age 16-65 years. WHO performance status grade 0-1. No concurrent serious medical condition that would preclude an allograft.
Study details: A phase II study of reduced intensity sibling allogeneic transplantation for relapsed, Chemosensitive, PET positive Hodgkin’s Lymphoma.
PAIRed
Type: Multicentre, phase II study
Eligibility: A confirmed diagnosis of Hodgkin Lymphoma. HLA-compatible sibling or unrelated donor (at least 9/10 match). Two Subgroups of patients (a) Primary refractory HL achieving <CR to on line of salvage chemotherapy, (b) HL in first relapse achieving <PR to one line of salvage chemotherapy. Age 16-65 years. WHO performance status grade 0-1. No concurrent serious medical condition that would preclude an allograft.
Study details: To document the toxicity, feasibility and survival following reduced intensity transplantation from HLA-compatible sibling or unrelated donors in patients with primary refractory or relapsed refractory Hodgkin Lymphoma.